AET remains a marginal player in the global enzymes landscape that is estimated at ~US$10 billion and poised to grow at 6-7% CAGR as more applications across usage industries incorporate enzymatic technologies It has got proven capabilities and stable financials, thanks to a mix of organic and inorganic growth strategy employed by management Going ahead, AET plans to augment its R&D; capability that bodes well in the long run in its quest to improve scalability & foraying into complex enzymes...